Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05666960 · ClinicalTrials.gov registry record · Phase 1
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
A Phase 1 study of Ulcerative Colitis and Ulcerative Colitis Chronic, sponsored by Rise Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 4
- Study locations
NCT05666960: Recruiting Phase 1 study of Ulcerative Colitis and Ulcerative Colitis Chronic, sponsored by Rise Therapeutics.
NCT05666960 is a Phase 1 study of Ulcerative Colitis and Ulcerative Colitis Chronic that is actively recruiting participants, run by Rise Therapeutics. The registered enrollment target is 36 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05666960, a Phase 1 study of Ulcerative Colitis and Ulcerative Colitis Chronic, is actively recruiting participants, sponsored by Rise Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate ulcerative colitis. Patients will take an oral dosage of probiotic (R-3750) and provide patient-reported and physician scored measures of their colitis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-3750) on fecal levels will also be measured.
Primary Outcome
To assess the number of participants with treatment-realated adverse events after taking R-3750 (probiotic)
Conditions Studied
Interventions
- DRUG R-3750
Study Locations (4)
Florida
- AP Medical Research LLC - Miami
- Edward Jenner Research Group, LLC - Plantation
California
- Amicis Research Center - Valencia
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
What NCT05666960 shows while recruiting
NCT05666960 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which R-3750 is the first listed.
NCT05666960 reports a single indexed study location in Florida, California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05666960 about?
NCT05666960 is a clinical study titled "R-3750 in Patients With Mild to Moderate Ulcerative Colitis". The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate ulcerative colitis. Patients will take an oral dosage of probiotic (R-3750) and provide patient-reported and physician scored measures of their colitis. Blood and ...
What is the current status of trial NCT05666960?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2023-02-27. Estimated completion is 2026-10.
What conditions does trial NCT05666960 study?
This clinical trial studies the following conditions: Ulcerative Colitis, Ulcerative Colitis Chronic, Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Mild.
What interventions are being tested in trial NCT05666960?
The interventions under investigation include: R-3750 (DRUG).
Who is sponsoring clinical trial NCT05666960?
This trial is sponsored by Rise Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05666960 being conducted?
This trial has 4 study locations across California, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05666960's enrollment target sits among peer trials
36 98th of 122 higher than 24 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Use of Butyrate Therapy in Pediatric Ulcerative Colitis
RECRUITING · Phase 1
-
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
RECRUITING · Phase 1
-
CP101 for the Treatment of Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 1
-
Angiographic Delivery of AD-MSC for Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis
COMPLETED · Phase 1
-
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI